These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 21165704)
41. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642 [TBL] [Abstract][Full Text] [Related]
42. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Steiner G Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129 [TBL] [Abstract][Full Text] [Related]
43. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
44. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks FM; Ridker PM Herz; 1999 Feb; 24(1):51-6. PubMed ID: 10093013 [TBL] [Abstract][Full Text] [Related]
45. Cholesterol and atherosclerosis: a contemporary perspective. Kashyap ML Ann Acad Med Singap; 1997 Jul; 26(4):517-23. PubMed ID: 9395824 [TBL] [Abstract][Full Text] [Related]
46. The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials. Ferdinand KC Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III12-5. PubMed ID: 15239486 [TBL] [Abstract][Full Text] [Related]
47. Lipid-modifying therapy in the elderly. Hamilton-Craig I; Colquhoun D; Kostner K; Woodhouse S; d'Emden M Vasc Health Risk Manag; 2015; 11():251-63. PubMed ID: 25999729 [TBL] [Abstract][Full Text] [Related]
48. Lipid lowering in high-risk populations: how low should we go? Watson K Ethn Dis; 2001; 11(4):834-7. PubMed ID: 11763308 [No Abstract] [Full Text] [Related]
49. Prevention of atherosclerosis progression in asymptomatic healthy elderly. Lees RS Am J Clin Nutr; 2007 Nov; 86(5):1569S-71S. PubMed ID: 17991677 [TBL] [Abstract][Full Text] [Related]
50. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)]. Föger B; Patsch JR Wien Klin Wochenschr; 2011 Jan; 123(1-2):21-7. PubMed ID: 21165704 [TBL] [Abstract][Full Text] [Related]